Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
65 hedge funds and large institutions have $31.9M invested in Eagle Pharmaceuticals, Inc. in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 28 reducing their positions, and 21 closing their positions.
93,325% more call options, than puts
Call options by funds: $3.74M | Put options by funds: $4K
13% less funds holding
Funds holding: 75 → 65 (-10)
43% less capital invested
Capital invested by funds: $55.5M → $31.9M (-$23.6M)
48% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 21
61% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.88M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$580K |
| 3 |
USPCM
Union Square Park Capital Management
New York
|
+$272K |
| 4 |
A
AJOVista
Boston,
Massachusetts
|
+$216K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$133K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSV Asset Management
Chicago,
Illinois
|
-$1.65M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.54M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.31M |
| 4 |
PA
Perceptive Advisors
New York
|
-$971K |
| 5 |
Millennium Management
New York
|
-$940K |
EGRX Hedge Fund Activity: Q3 2024 in Review
65 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q3 2024, worth a combined $31.9M — down 43% from $55.5M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of EGRX and 11 opened new positions — a net loss of 10 holders — while 28 trimmed existing stakes and 11 added.
The largest buyer was Nantahala Capital Management, adding an estimated $1.88M. The largest seller was LSV Asset Management, exiting entirely with an estimated $1.65M sold.
- 65 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q3 2024, down from 75 in Q2 2024.
- Funds reported $31.9M of Eagle Pharmaceuticals, Inc. stock for Q3 2024, down 43% quarter-over-quarter.
- 11 funds opened new Eagle Pharmaceuticals, Inc. positions in Q3 2024 and 21 closed out, a net change of -10 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q3 2024 was Nantahala Capital Management, an estimated $1.88M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q3 2024 was LSV Asset Management, an estimated $1.65M sold.
Based on aggregated 13F filings for Q3 2024.